SCHEDULE: Nomura Holdings Discloses 5.4% Stake in Charles River Labs

Nomura Holdings Inc. has disclosed a 5.4% passive beneficial ownership stake in Charles River Laboratories International, Inc., totaling 2,681,669 shares.

Summary

• Nomura Holdings Inc. reported beneficial ownership of 2,681,669 shares of Charles River Laboratories International, Inc. common stock.
• This stake represents 5.4% of the outstanding common stock of Charles River Laboratories International, Inc.
• The ownership includes shares held directly by Nomura Global Financial Products, Inc. (NGFP) and Nomura Securities International, Inc. (NSI), both wholly owned subsidiaries of Nomura Holdings Inc.
• NGFP beneficially owns 473,087 shares and 1,100,000 shares underlying call options exercisable within 60 days.
• NSI beneficially owns 1,096,182 shares and 12,400 shares underlying call options exercisable within 60 days.
• The percentage of class is calculated based on 49,209,000 shares of common stock outstanding as of June 28, 2025, as reported in the Issuer's quarterly report on Form 10-Q.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a major financial institution like Nomura Holdings Inc. is generally viewed positively, indicating institutional confidence in the company's long-term value without implying an activist intent.

Positives

• A major global financial institution, Nomura Holdings Inc., has taken a significant passive stake, indicating institutional confidence in the company's value and long-term prospects.
• The investment includes a substantial number of shares underlying call options, suggesting a potentially bullish outlook on the stock's future performance.

Risks

• The securities were acquired and are held in the ordinary course of business and are not intended for the purpose or with the effect of changing or influencing the control of the issuer.

Future Outlook

The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This suggests a passive, long-term investment strategy by Nomura Holdings Inc.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing reflects a significant passive investment by a major global financial institution in a leading contract research organization (CRO) within the life sciences sector. Such investments are common for large asset managers seeking exposure to specific industries or companies they deem undervalued or poised for growth, aligning with broader trends of institutional interest in the healthcare and biotechnology sectors.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability and potentially attract further investment, signaling a vote of confidence from a major financial player.
• Employees, Customers, Suppliers, Creditors: No direct or immediate impact is expected from this passive ownership disclosure.

Next Steps

• Continued passive holding of the disclosed stake by Nomura Holdings Inc. and its subsidiaries.

Key Dates

Recommendation

The acquisition of a significant passive stake by a reputable financial institution like Nomura Holdings Inc. suggests a positive long-term outlook for Charles River Laboratories. This institutional endorsement, while not indicative of active management involvement, can be interpreted as a vote of confidence in the company's fundamentals and future prospects, making it an attractive consideration for investors.

Keywords

Charles River Laboratories, Nomura Holdings, CRL, 13G, beneficial ownership, institutional investment, common stock, life sciences, contract research organization